

CHARLES ARTHUR PELOQUIN, PHARM.D.

CURRICULUM VITAE

I. Personal History

Present Rank: Professor

Present Address: 4404 NW 51st Drive, Gainesville, FL 32606

Citizenship: USA

II. Educational History

12/81 Bachelor of Science, Pharmacy (Magna cum Laude), University of Connecticut

5/86 Doctor of Pharmacy, Philadelphia College of Pharmacy and Science

III. Professional History

5/80 – 9/80 Medicinal Chemist, University of Connecticut School of Pharmacy, Storrs
5/81 – 9/81 Medicinal Chemist, University of Connecticut School of Pharmacy, Storrs
12/81 – 7/82 Intern in Pharmacy, Saint Francis Hospital and Medical Center, Hartford, CT
7/82 – 6/83 A.S.H.P. Resident in Hospital Pharmacy Duke University Medical Center, Durham, NC
7/83 – 2/84 Clinical Pharmacist, General Surgery, Duke University Medical Center
3/84 – 8/84 Clinical Pharmacist, General Medicine, Duke University Medical Center
8/84 – 3/85 Staff Pharmacist Thomas Jefferson University Hospital, Philadelphia, PA
7/86 – 8/88 A.C.C.P. Fellow, Infectious Diseases and Pharmacokinetics
The Clinical Pharmacokinetics Laboratory, Millard Fillmore Hospital, Buffalo, NY
7/88 – 3-09 Director, Infectious Disease Pharmacokinetics Laboratory
National Jewish Health, 1400 Jackson Street, Denver, CO 80206

7/88 Assistant Faculty Member, Department of Medicine
4/94 Associate Faculty Member, Department of Medicine
7/01 Senior Faculty Member, Department of Medicine
National Jewish Medical and Research Center

9/88 – 12/94 Adjoint Assistant Professor of Pharmacy
1/95 – 11/01 Adjoint Associate Professor of Pharmacy
11/01 – 9/05 Adjoint Professor of Pharmacy
9/05 – 3/09 Clinical Professor of Pharmacy
University of Colorado School of Pharmacy, Denver, CO

7/93 – 12/94 Adjoint Assistant Professor of Medicine
1/95 – 11/01 Adjoint Associate Professor of Medicine
11/01 – 9/05 Adjoint Professor of Medicine
9/05 – 3/09 Clinical Professor of Medicine, Division of Infectious Diseases
University of Colorado School of Medicine, Denver, CO

III. Professional History

- 3/09 – present Professor, and Director
Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy,
and Emerging Pathogens Institute, University of Florida, Gainesville, FL
- 2/11 – present Professor, College of Medicine, University of Florida

III a. Professional Licenses (Registered Pharmacist)

- 1982 State of Connecticut (#5884)
1984 Commonwealth of Pennsylvania (inactive)
1993 Clinical Lab. Director, TDM, New York State (#PELOC1)
1989 State of Colorado (#12831, inactive)
2009 State of Florida Clinical Lab Director, LTD (#42669)

IV. Honors and Awards

- 1980-present Rho Chi Honor Society
1981 University of Connecticut Honor Scholar
1987-1988 ACCP Infectious Disease Research Fellow
2010 FCCP, Fellow of the American College of Clinical Pharmacy
2014 UF Research Foundation Professor
2017 UF Term Professor

V. Professional Affiliations

- 1982-2004 American Society of Health Systems Pharmacists
1986-present American College of Clinical Pharmacy
1989-2003 Colorado Society of Hospital Pharmacists
1990-present American Society of Microbiology
1991-present Society of Infectious Disease Pharmacists
1995-present International Union Against Tuberculosis and Lung Disease
2004-present International Society of Antimicrobial Pharmacology
2013-present National Tuberculosis Controllers Association

VI. Professional Service and Committees

A. Institutional and Departmental Committees

- 2009 UF Clinical and Translational Science Institute (CTSI) Translational Science
Advisory Committee (TSAC)
2010-2015 COP Tenure and Promotion Committee (Chair 2013-2015)
2011-2012 Facilities & Resources Sub-Committee
2011-2013 Professionalism Committee
2015 Prosper Review Committee
2015-present Research Strategic Planning Task Force
2010-present Numerous other recruitment and ad hoc committees

VI. Professional Service and Committees

B. National Service

- 2000-2009 Grant Reviewer for the U.S. Civilian Research and Development Foundations
2006 - present NIH Committee on Guidelines for the Prevention and Treatment
of Opportunistic Infections in Patients with HIV

2009 Participant, FDA Conference on Issues in the Design of Clinical Trials of Antimycobacterial Drugs for the Treatment of Tuberculosis. Silver Spring, MD, July 30-31, 2009

2013 – present ATS/CDC/IDSA/AAP TB Treatment Guidelines Revision

2014 – present American Thoracic Society (ATS) Project Committee: Setting a Prioritized Research Agenda for Nontuberculous Mycobacterial Infections

C. International Service

- 2007 – present Organizing Committee, International Workshop on
Clinical Pharmacology of Tuberculosis Drugs
 1st Workshop, Toronto, Ontario, Canada, May 15, 2008
 2nd Workshop, San Francisco, CA, September 11, 2009
 3rd Workshop, Boston, MA, September 11, 2010
 4th Workshop, Chicago, IL, September 16, 2011
 5th Workshop, San Francisco, CA, September 8, 2012
 6th Workshop, Denver, CO, September 9, 2013
 7th Workshop, Washington, DC, September 5, 2014
 8th Workshop, San Diego, CA, September 17, 2015
 9th Workshop, Liverpool, UK, October 24, 2016
 10th Workshop, Atlanta, GA, October 15, 2017
- 2008 Participant, Workshop on Clinical Trials for Drug-Resistant Tuberculosis, Cambridge, MA, USA, 10-12 June 2008
- 1991-2015 Department of Health and Human Services (DHHS):
The Food and Drug Administration
The Center for Disease Control and Prevention
(Ad hoc) AIDS Clinical Trials Group (ACTG)
(Ad hoc) Community Programs for Clinical Research on AIDS (CPCRA)
- Industry: Jacobus Pharmaceuticals, Dura Pharmaceuticals, Coretech,
Hoechst Marion Roussel / Sanofi Aventis, Pharmacia / Pfizer, Tibotec, Otsuka

VII. Patents

None. Methods for the determination of antimycobacterial drug concentrations remain proprietary information.

VIII. Review and Referee Activities

Journal Referee:

Regular:

- 1990 - present Pharmacotherapy
1997 - present International Journal of Tuberculosis and Lung Disease
1997 - present Clinical Infectious Diseases
1998 - present Antimicrobial Agents and Chemotherapy
2001 - present Journal of Antimicrobial Chemotherapy

Occasional:

Annals of Pharmacotherapy, Journal of Infectious Disease Pharmacotherapy
American Journal of Respiratory and Critical Care Medicine
Journal of the American Medical Association, Drugs, Tubercle and Lung Disease, Tuberculosis
New England Journal of Medicine, Chest, Clinical Pharmacokinetics
Journal of Chromatography B, Biomedical Sciences and Applications
American Journal of Medicine, The Lancet
Journal of Pharmacy and Pharmacology, International Journal of Pharmaceutics
British Journal of Pharmacology, Pharmaceutical Research,
Chemotherapy, mBio, J Theoretical Biology, Thorax, Current Opinion in Pharmacology,
Journal of Infectious Diseases, Pakistan Journal of Scientific and Industrial Research

Study review: (occasional)

1993 - present Grant Reviewer for the World Health Organization
2000 - present Grant Reviewer for Ontario HIV Treatment Network
2010 - present NIH

IX. Teaching Activities

2010 - present College of Pharmacy, University of Florida
PharmD Lectures: Pharmacotherapy III and V, Infectious Diseases
Graduate Lectures, WPPD and Masters Courses
Undergraduate, professional, and graduate students in the lab

Graduate Students

Eric Egelund, Pharm.D. Ph.D. candidate 2010 – 2014
Aline Barth, Pharm.D. (co-preceptor, Hartmut Derendorf, Ph.D.) Ph.D. candidate 2011 – 2014
Abdullah Alsultan, Pharm.D. Ph.D. candidate 2012 – 2016
Marc Tobias Heinrichs, B.S. (co-preceptor, Hartmut Derendorf, Ph.D.) Ph.D. candidate 2014 –2017
Wael Alghamdi, Pharm.D. candidate 2016-
Mohammad Alshaer, Pharm.D. candidate 2016-

Clinical Pharmacy Resident

Shaun Berning, Pharm.D. June 1991 – May 1992
Current: Director, Distance Degrees and Programs; Associate Professor, University of Colorado College of Pharmacy

Fellows / Research Associates

Amy Bulpitt, B.S. Pharmacy, R.Ph. June 1996 to July 1997
NIH RO1 AI37845 Research Associate
Current: Pharmacist, Swedish Medical Center, Denver

Rocsanna Namdar, Pharm.D. June 1997 to July 1998
NIH RO1 AI37845 Research Associate
Current: Rocsanna Namdar, Pharm.D., FCCP, BCPS, VAMC, Albuquerque, NM

Rebecca Malone, Pharm.D. June 1997 to July 1999
FDA Orphan Product Division FD-R-000812-01 Research Associate
Current: Clinical Pharmacist, University of Arizona, Tucson, AZ

Barbara Auclair, Pharm.D. November 1998 to November 1999
NIH RO1 AI37845 Research Associate
Current: Pharmacist, Greenville, SC

Min Zhu, Ph.D. December 1999 to September 2000
NIH RO1 AI37845 Research Associate
Current: Director, Clinical Pharmacology at Regeneron Pharmaceuticals, Inc., New York

Bryan McGee, Pharm.D. September 2007 to September 2008
CU HIV Training Grant
Current: Senior Medical Science Liaison at Agios Pharmaceuticals, Denver, CO

| | |
|--------------|-----------------------------------------------------------------|
| IX a. | Specialized Training |
| March 2013 | Intermediate PK/PD Modeling Methodology Using Phoenix WinNonlin |
| January 2015 | Advanced PK/PD Modeling Methodology Using Phoenix WinNonlin |

IX b. Annual Continuing Education

All requirements met for Pharmacist's license since 1981

All requirements met for University of Florida since 2009

All requirements met for Florida Clinical Laboratory Technologist license since 2009

X. Research Grants, Contracts, and Special Grants

See attached spreadsheet from COP Research Support

X a. Clinical Program Revenues

Revenue for Laboratory Services:

The Infectious Disease Pharmacokinetics Laboratory

Founder and Director: Charles A. Peloquin, Pharm.D.

The IDPL is the nation's only reference laboratory specializing in therapeutic drug monitoring and interpretation for all of the antimycobacterial drugs, plus antifungal and anti-HIV drugs.

Total Gross Revenue:

University of Florida \$ 3,260,252

Fiscal Year 2018: *\$600,000 projected*

Fiscal Year 2017: \$572,070

Fiscal Year 2016: \$419,650

Fiscal Year 2015: \$381,899

Fiscal Year 2014: \$470,475

Fiscal Year 2013: \$438,134

Fiscal Year 2012: \$419,932

Fiscal Year 2011: \$424,492

Fiscal Year 2010: \$133,600

XI. Bibliography

A. Original research papers published in refereed journals (from 2009)

(total 168 papers: 21 first author, 46 senior author, 101 other)

88. Sung JC, Garcia-Contreras L, VerBerkmoes JL, **Peloquin CA**, Elbert KJ, Hickey AJ, Edwards DE. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. *Antimicrobial Agents and Chemotherapy* 2009; 53: 1338-1343. Epub 2009 Jan 12. PMID: 19139288
89. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, **Peloquin CA**, Stout JE. Therapeutic drug monitoring in patients with tuberculosis and advanced human immunodeficiency virus infection. *Pharmacotherapy* 2009; 29: 503–510. PMID: 19397460
90. Sung JC, Garcia-Contreras L, VerBerkmoes JL, Padilla DJ, **Peloquin CA**, Elbert KJ, Hickey AJ, Edwards DE. Formulation and Pharmacokinetics of Self-Assembled Rifampicin Nanoparticle Systems for Pulmonary Delivery. *Pharmaceutical Research* 2009; 26: 1847-1855. Epub 2009 Apr 30. PMID: 19407933
91. Chideya S, Winston CA, **Peloquin CA**, Bradford WZ, Hopewell PC, Wells, CD, Reingold AL, Kenyon TA, Moeti TL, Tappero JW. Isoniazid, Rifampin, Ethambutol and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis – Botswana. *Clin Infect Dis.* 2009; 48: 1685-1694. PMID: 19432554
92. McGee B, Dietze R, Hadad DJ, Molino LP, Maciel EL, Boom WH, Palaci M, Johnson JL, Peloquin CA. Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis. *Antimicrob Agents Chemother.* 2009; 53: 3981-3984. Epub 2009 Jun 29. PMID: 19564361
93. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J. Paradoxical effect of isoniazid on the activity of the rifampin-pyrazinamide combination in the mouse model of tuberculosis. *Antimicrob Agents Chemother.* 2009; 53: 4178-4184. Epub 2009 Jul 20. PMID: 19620331
94. Barroso EC, Pinheiro VGF, Facanha MC, Carvalho MRD, Moura ME, Campelo CL, **Peloquin CA**, Guerrant RL, Lima AAM. Serum concentrations of rifampin, isoniazid, and intestinal absorption, permeability in patients with multidrug resistant tuberculosis. *American Journal of Tropical Medicine and Hygiene* 2009; 81: 332-329. PMID: 19635892
95. Ahmad Z, Klinkenberg KG, Pinn ML, Fraig MM, **Peloquin CA**, Bishai WR, Nuermberger EL, Grosset JG, Karakousis PC. Biphasic Kill Curve of Isoniazid Reveals the Presence of Drug-Tolerant, Not Drug-Resistant, *Mycobacterium tuberculosis* in the Guinea Pig. *J Infect Dis.* 2009 Oct 1; 200: 1136-1143. Aug 17. [Epub ahead of print] PMID: 19686043
96. Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, **Peloquin CA**. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. *Clinical Infectious Diseases* 2009; 49: 1305-1311. PMID: 19807276
97. Luber A, Condoluci D, Slowinski P, Andrews M, Olson K, **Peloquin C**, Pappa K, Pakes G; for the COL104422 Study Team. Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. *HIV Med.* 2010 Mar;11(3):193-9. Epub 2009 Oct 23. PMID: 19863619

A. Original research papers published in refereed journals (from 2009)

98. Ahmad Z, Nuermberger EL, Tasneen R, Pinn ML, Williams KN, **Peloquin CA**, Grosset JH, Karakousis PC. Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. *J Antimicrob Chemother.* 2010 Apr;65(4):729-34. Epub 2010 Jan 31. PMID: 20123722
99. Weinberg A, Forster-Harwood J, McFarland E, Pappas J, Davies J, Kinzie K, Barr E, Paul S, Salbenblatt C, Soda E, Vazquez A, **Peloquin CA**, Levin M. Kinetics and Determining Factors of the Virologic Response to Antiretrovirals During Pregnancy. *Infect Dis Obstet Gynecol.* 2009;2009:621780. Epub 2010 Jan 10. PMID: 20130816
100. Façanha MC, Gondim AM, Pinheiro VG, Barroso EC, Peloquin CA, Guerrant RL, Lima AA. Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis. *Braz J Infect Dis.* 2009 Jun;13(3):210-7. PMID: 20191199
101. Weiner M, **Peloquin C**, Burman W, Luo CC, Engle M, Prihoda T, Mac Kenzie W, Bliven-Sizemore E, Johnson J, Vernon A for the Tuberculosis Trials Consortium. The effects of tuberculosis, race and human gene *SLCO1B1* polymorphisms on rifampin concentrations. *Antimicrob Agents Chemother.* 2010 Jul 26. [Epub ahead of print] PMID: 20660695
102. Ahmad Z, Pinn ML, Nuermberger EL, **Peloquin CA**, Grosset JH, Karakousis PC. The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. *J Antimicrob Chemother.* 2010 Aug 6. [Epub ahead of print] PMID: 20693172
103. Ahmad Z, **Peloquin CA**, Singh RP, Derendorf H, Tyagi S, Ginsberg A, Grosset JH, Nuermberger EL. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. *Antimicrob Agents Chemother.* 2010 Oct 11. [Epub ahead of print] PMID: 20937781
104. De Groote MA, Gilliland JC, Wells CL, Brooks E, Woolhiser LK, Gruppo VR, **Peloquin CA**, Orme IM, Lenaerts A. Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against *M. tuberculosis*. *Antimicrobial Agents and Chemotherapy* 2010 Dec 6. [Epub ahead of print]
105. Ahmad Z, Minkowski A, **Peloquin CA**, Williams K, Grosset JH, Nuermberger EL. Activity of the fluoroquinolone DC-159a in the initial and continuation treatment of murine tuberculosis. *Antimicrob Agents Chemother.* 2011 Jan 31. [Epub ahead of print]
106. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, **Peloquin CA**, Nuermberger EL, Grosset JH. Treatment of Tuberculosis with Rifamycin-containing Regimens in Immune Deficient Mice *Am J Respir Crit Care Med.* 2011 May 1;183(9):1254-61. Epub 2011 Feb 17. PMID: 21330452
107. Tasneen R, Li SY, **Peloquin CA**, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. *Antimicrob Agents Chemother.* 2011 Sep 19. [Epub ahead of print], print *Antimicrob Agents Chemother.* 2011; 55: 5485-5492.
108. Rhoades JA, Peterson YK, Zhu HJ, Appel DI, **Peloquin CA**, Markowitz JA. Prediction and in vitro evaluation of selected protease inhibitor antiviral drugs as inhibitors of carboxylesterase 1: a potential source of drug-drug interactions. *Pharmaceutical Research Pharm Res.* 2012; 29:972-82. Epub 2011 Dec 9. [Published online Dec 09, 2011]

A. Original research papers published in refereed journals (from 2009)

109. Williams K, Minkowski A, Amoabeng O, **Peloquin CA**, Taylor D, Andries K, Wallis WS, Mdluli KE, Nuermberger EL. Sterilizing activity of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. *Antimicrob Agents Chemother.* 2012 Jun;56(6):3114-20. Epub 2012 Apr 2. PMID: 22470112
110. Tsuji BT, Brown T, Parasrampur R, Brazeau D, Forrest A, Kelchlin PA, Holden PN, **Peloquin CA**, Hanna D, Bulitta J. Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 2012 Jul;56(7):3712-9. Epub 2012 Apr 23. PMID: 22526313
111. Dutta NK, Illei PB, **Peloquin CA**, Pinn ML, Nuermberger EL and Karakousis PC. Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. *Antimicrob Agents Chemother.* 2012 Jul;56(7):3726-31. Epub 2012 Apr 30. PMID: 22547623
112. Rosenthal IM, Tasneen R, **Peloquin CA**, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. *Antimicrob Agents Chemother.* 2012 Aug;56(8):4331-40. doi: 10.1128/AAC.00912-12. Epub 2012 Jun 4. PMID: 22664964
113. Tsuji BT, Brown T, Bulitta J, Forrest A, Brazeau D, Kelchlin PA, Holden PN, **Peloquin CA**, Skerlos L, Hanna D. Pharmacodynamics of Early, High Dose Linezolid against Vancomycin-Resistant Enterococci (VRE) with Elevated MICs and Pre-Existing Genetic Mutations. *J Antimicrob Chemother.* 2012 Sep;67(9):2182-90. doi: 10.1093/jac/dks201. Epub 2012 Jun 8. PMID: 22685161
114. van Ingen J, Egelund EF**, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, **Peloquin CA**, Daley CL.. The Pharmacokinetics and Pharmacodynamics of Pulmonary Mycobacterium Avium Complex Disease Treatment. *Am J Respir Crit Care Med.* 2012 Sep 15;186(6):559-65. doi: 10.1164/rccm.201204-0682OC. Epub 2012 Jun 28. PMID: 22744719
115. Matthias KR, Nix DE, **Peloquin CA**, Graham ML. Poor Absorption of High-Dose Posaconazole in Pediatric Bone Marrow Transplant Patients. *Ann Pharmacother.* 2012 Sep;46(9):e22. doi: 10.1345/aph.1Q456. Epub 2012 Aug 7. PMID: 22872751
116. Glover TL, Goodin BR, Horgas AL, Kindler LL, King CB, Sibille K, **Peloquin CA**, Riley III, JR, Staud R, Bradley LA, Fillingim RB. Vitamin D, Race, and Pain. *Arthritis Rheum.* 2012 Dec;64(12):3926-35. doi: 10.1002/art.37687. PMID: 23135697
117. Dutta NK, Alsultan A, **Peloquin CA**, Karakousis PC. Preliminary pharmacokinetic study of repeated doses of rifampin and rifapentine in guinea pigs. *Antimicrob Agents Chemother.* 2013 Mar;57(3):1535-7. doi: 10.1128/AAC.01933-12. Epub 2013 Jan 7. PMID: 2329592
118. Egelund EF**, Egelund TA, Ng JS, Wassil SK, **Peloquin CA**. Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis. *Pharmacotherapy.* 2013 Jan;33(1):e1-8. doi: 10.1002/phar.1172. PMID: 23307552

A. Original research papers published in refereed journals (from 2009)

119. Ahmad Z, Tyagi S, Minkowski A, **Peloquin CA**, Grosset JH, Nuermberger EL. Contribution of Moxifloxacin or Levofloxacin in Second-line Regimens with or without Continuation of Pyrazinamide in Murine Tuberculosis. *Am J Respir Crit Care Med*. 2013 Jul 1;188(1):97-102. doi: 10.1164/rccm.201212-2328OC. PMID: 23593945
120. Dutta NK, Alsultan A, Gniadek TJ, Belchis DA, Pinn ML, Mdluli KE, Nuermberger EL, **Peloquin CA**, Karakousis PC. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. *Antimicrob Agents Chemother*. 2013 Aug;57(8):3910-6. doi: 10.1128/AAC.00761-13. Epub 2013 Jun 3. PMID: 23733473
121. Mpagama SG, Ndusilo N, Stroup S, Kumburu H, **Peloquin CA**, Gratz J, Moore JL, Houpt ER, Kibiki GS, Heysell SK Plasma drug activity in multidrug-resistant tuberculosis. *Antimicrob Agents Chemother*. 2014 Feb;58(2):782-8. doi: 10.1128/AAC.01549-13. Epub 2013 Nov 18. PMID: 24247125
122. Weiner M, Egelund EF, Engle M, Kiser M, Prihoda TJ, Gelfond JAL, Mac Kenzie W, **Peloquin CA**. The Pharmacokinetic Interaction Between Raltegravir and Rifapentine in Healthy Volunteers. *J Antimicrob Chemother*. 2014 Apr;69(4):1079-85. doi: 10.1093/jac/dkt483. Epub 2013 Dec 15. PMID: 24343893
123. Weiner M, Savic RM, Mac Kenzie WR, Wing D, **Peloquin CA**, Engle M, Bliven E, Borisov A, Prihoda TJ, Gelfond J, Wing R, Abdel-Rahman SM, Kearns GL, Burman WJ, Sterling TR, Villarino ME Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly with Rifapentine and Isoniazid for Latent Tuberculosis Infection. *Journal of the Pediatric Infectious Diseases Society* pp. 1-14, 2014. DOI:10.1093/jpids/pit077
124. Kwara A, Cao L, Poethke P, Kurpewski KT, Mahjoub B, Court MH, **Peloquin CA**. Factors Associated with Variability in Rifampin Plasma Pharmacokinetics and the Relationship between Rifampin Concentrations and Drug Interactions with Efavirenz. *Pharmacotherapy*. 2014 Mar;34(3):265-71. doi: 10.1002/phar.1388. Epub 2014 Jan 13. PMID: 24420746
125. Brock AP, Isaza R, Egelund EF, Hunter RP, and **Peloquin CA**. The Pharmacokinetics of a Single Oral or Rectal Dose of Concurrently Administered Isoniazid, Rifampin, Pyrazinamide, and Ethambutol in Asian Elephants (*Elephas maximus*). *J Vet Pharmacol Ther*. 2014 Mar 29. doi: 10.1111/jvp.12119. [Epub ahead of print] PMID: 24684601
126. Egelund EF, Weiner W, Singh Rp, Prihoda TJ, Derendorf H, Mac Kenzie WR, and **Peloquin CA**. Protein Binding of Rifapentine and the 25-Desacetyl Metabolite in Patients with Pulmonary Tuberculosis. *Antimicrob Agents Chemother*. 2014 May 19. pii: AAC.01730-13. [Epub ahead of print] PMID: 24841270
127. Drusano GL, Neely M, Van Guilder M, Schumitzky A, Brown D, Fikes S, **Peloquin C**, Louie A. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. *PLoS One*. 2014 Jul 8;9(7):e101311. doi: 10.1371/journal.pone.0101311. eCollection 2014. PMID: 25003557

A. Original research papers published in refereed journals (from 2009)

128. Egelund EF, Isaza R, Brock AP, Alsultan A, An G, **Peloquin CA**. Population Pharmacokinetics of Rifampin in the treatment of *Mycobacterium tuberculosis* in Asian Elephants. *J. Vet. Pharmacol. Therap.* doi: 10.1111/jvp.12156 [Sept 2014]
129. Kempker R, Barth B, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, Bablishvili N, Singh R, Guarner J, Derendorf H, **Peloquin CA**, Blumberg H. Cavitary Penetration of Levofloxacin among Patients with Multidrug-Resistant Tuberculosis. *Antimicrob Agents Chemother.* 2015 Mar 16. pii: AAC.00379-15. [Epub ahead of print] PMID: 25779583
130. Tucker L, Higgins T, Egelund EF, Zou B, Vijayan V, and **Peloquin CA**. Voriconazole Monitoring in Children with Invasive Fungal Infections. *The Journal of Pediatric Pharmacology and Therapeutics* 2015; 20: 17-23. doi: 10.5863/1551-6776-20.1.17. PMID: 25859166
131. Heysell SK, Moore JL, **Peloquin CA**, Ashkin D, Houpt ER. Outcomes and use of therapeutic drug monitoring in multidrug-resistant TB patients treated in Virginia, 2009-2014. *Tuberculosis and Respiratory Disease.* 2015; 78: 78-84. doi: 10.4046/trd.2015.78.2.78. Epub 2015 Apr 2. PMID: 25861340
132. Alsultan A, An G, **Peloquin CA**. Limited Sampling Strategy and Target Attainment Analysis for Levofloxacin in Patients with Tuberculosis. *Antimicrob Agents Chemother.* 2015 Apr 13. pii: AAC.00341-15. [Epub ahead of print] PMID: 25870068
133. Kwara A, Enimil A, Gillani FS, Yang H, Sarfo AM, Dompok A, Ortsin A, Osei-Tutu L, Kwarteng Owusu S, Wiesner L, Norman J, Kurpewski J, Peloquin CA, Ansong D, Antwi S. Pharmacokinetics of First-Line Antituberculosis Drugs Using WHO Revised Dosage in Children With Tuberculosis With and Without HIV Coinfection. *J Pediatric Infect Dis Soc.* 2015 May 26. pii: piv035. [Epub ahead of print] PMID: 26407268
134. Long R, Barrie J, **Peloquin CA**. Therapeutic drug monitoring and the conservative management of chronic tuberculous empyema: case report and review of the literature. *BMC Infect Dis.* 2015 Aug 12;15:327. doi: 10.1186/s12879-015-1093-7. PMID: 26265445
135. Mase SR, Jereb JA, Gonzalez D, Martin F, Daley CL, Fred D, Loeffler A, Menon L, Morris SB, Brostrom R, Chorba T, **Peloquin CA**. Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-Resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands. *Pediatr Infect Dis J.* 2015 Dec 10. [Epub ahead of print] PMID: 26658531
136. Hennig S, Svensson EM, Niebecker R, Fourie PB, Weiner MH, Bonora S, **Peloquin CA**, Gallicano K, Flexner C, Pym A, Vis P, Olliaro PL, McIlleron H, Karlsson MO. Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. *J Antimicrob Chemother.* 2016 Jan 31. pii: dkv470. [Epub ahead of print] PMID: 26832753
137. Bannietts N, Sharma R, Hand I, **Peloquin CA**, Kohlhoff S, Hammerschlag MR. Steady-state pharmacokinetics of oral linezolid suspension in a premature infant with osteomyelitis. *J Antimicrob Chemother.* 2016 Feb 6. pii: dkv507. [Epub ahead of print] PMID: 26851607

A. Original research papers published in refereed journals (from 2009)

138. Hope WW, Walsh TJ, Goodwin J, **Peloquin CA**, Howard A, Kurtzberg J, Mendizabal A, Confer DL, Bulitta J, Baden LR, Neely MN, Wingard JR for the Blood and Marrow Transplant Clinical Trials Network. Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. *J Antimicrob Chemother.* 2016 Apr 27. pii: dkw127. [Epub ahead of print] PMID: 27121401
139. Zentner I, Schlecht HP, Khensouvann L, Tamuhla N, Kutzler M, Ivaturi V, Pasipanodya JG, Gumbo T, **Peloquin CA**, Bisson GP, Vinnard C. Urine colorimetry to detect Low rifampin exposure during tuberculosis therapy: a proof-of-concept study. *BMC Infect Dis.* 2016 Jun 1;16(1):242. doi: 10.1186/s12879-016-1576-1. PMID: 27250739
140. Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, **Peloquin CA**, Alsultan A, Thiel B, Debanne SM, Boom WH, Diacon AH, Johnson JL. Early Bactericidal Activity of AZD5847 in Pulmonary Tuberculosis. *Antimicrob Agents Chemother.* 2016 Aug 22. pii: AAC.01163-16. [Epub ahead of print] PMID: 27550361
141. Milstein M, Lecca L, **Peloquin C**, Mitchison D, Seung K, Pagano M, Coleman D, Osso E, Coit J, Vargas Vasquez DE, Sanchez Garavito E, Calderon R, Contreras C, Davies G, Mitnick CD. Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. *BMC Infect Dis.* 2016 Aug 27;16(1):453. doi: 10.1186/s12879-016-1790-x. PMID: 27567500
142. Eric F. Egelund, Ramiro Isaza, Abdullah Alsultan, **Charles A. Peloquin**. Isoniazid and Rifampin Pharmacokinetics in Two Asian Elephants (*Elephas Maximus*) Infected with Tuberculosis. *Journal of Zoo and Wildlife Medicine* 2016 Sep;47(3):868-871. PMID: 27691967
143. Garcia-Contreras L, Padilla-Carlin DJ, Sung J, VerBerkmoes J, Muttill P, Elbert K, **Peloquin C**, Edwards D, Hickey A. Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs. *J Pharm Sci.* 2016 Nov 11. pii: S0022-3549(16)41775-2. doi:10.1016/j.xphs.2016.09.033. [Epub ahead of print] PMID: 27842973
144. Simpson G, Zimmerman R, Shashkina E, Chen L, Richard M, Bradford CM, Dragoo GA, Saiers RL, **Peloquin CA**, Daley CL, Planet P, Narachenia A, Mathema B, Kreiswirth BN. Mycobacterium tuberculosis Infection among Asian Elephants in Captivity. *Emerg Infect Dis.* 2017 Mar;23(3):513-516. doi: 10.3201/eid2303.160726.
145. Savic RM, Weiner M, MacKenzie WR, Engle M, Whitworth WC, Johnson JL, Nsubuga P, Nahid P, Nguyen NV, **Peloquin CA**, Dooley KE, Dorman SE; Tuberculosis Trials Consortium of the Centers for Disease Control and Prevention. Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two phase II clinical trials. *Clin Pharmacol Ther.* 2017 Jan 25. doi: 10.1002/cpt.634. [Epub ahead of print] PMID: 28124478
146. Antwi S, Yang H, Enimil A, Sarfo AM, Gillani FS, Ansong D, Dompreeh A, Orstin A, Opoku T, Bosumtwe D, Wiesner L, Norman J, **Peloquin CA**, Kwara A. Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection. *Antimicrob Agents Chemother.* 2017 Jan 24;61(2). pii: e01701-16. doi: 10.1128/AAC.01701-16. [Epub ahead of print] PMID: 27855070

A. Original research papers published in refereed journals (from 2009)

147. Abdullah Alsultan, Rada Savic, Kelly E. Dooley, Marc Weiner, William Whitworth, William R. Mac Kenzie, **Charles A. Peloquin** and the Tuberculosis Trials Consortium. Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. AAC Accepted Manuscript Posted Online 13 March 2017 Antimicrob. Agents Chemother. doi:10.1128/AAC.02625-16
148. Hamadeh IS, Klinker KP, Borgert SJ, Richards AI, Li W, Mangal N, Hiemenz JW, Schmidt S, Langae TY, **Peloquin CA**, Johnson JA, Cavallari LH. Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections. Pharmacogenet Genomics. 2017 Mar 16. doi:10.1097/FPC.0000000000000277. [Epub ahead of print] PMID: 28306618
149. Kempker RR, Heinrichs MT, Nikolaishvili K, Sabulua I, Bablishvili N, Gogishvili S, Avaliani Z, Tukvadze N, Little B, Bernheim A, Read TD, Guarner J, Derendorf H, **Peloquin CA**, Blumberg HM, Vashakidze S. Lung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis. Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.00226-17. doi: 10.1128/AAC.00226-17. [Epub ahead of print] PMID: 28373198
150. Haraus EP, Leigh J, Garcia-Prats AJ, Furin J, **Peloquin CA**. Stability of Second-Line Tuberculosis Medications Mixed with Milk or Yogurt. Clin Infect Dis. 2017 May 6. doi: 10.1093/cid/cix434. [Epub ahead of print] No abstract available. PMID: 28482036
151. **Peloquin CA**, Velásquez GE, Lecca L, Calderón RI, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Mitnick CD, Davies G. Pharmacokinetic evidence to support increased doses of rifampin for tuberculosis: results from the HIRIF trial. Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00038-17. doi: 10.1128/AAC.00038-17. [Epub ahead of print] PMID: 28559269 Erratum Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e01524-17. doi: 10.1128/AAC.01524-17. Print 2017 Sep. PMID: 28839086
152. Browne SH, **Peloquin C**, Santillo F, Haubrich R, Muttera L, Moser K, Savage G, Benson C, Blaschke T. Digitizing Medicines for remote capture of oral medication adherence using Co-encapsulation. Clin Pharmacol Ther. 2018 Mar;103(3):502-510. doi: 10.1002/cpt.760. Epub 2017 Sep 19. PMID: 28597911
153. Thakkar N, Guptill JT, Aleš K, Jacobus D, Jacobus L, **Peloquin C**, Cohen-Wolkowicz M, Gonzalez D; DAPPER Study Group. Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients with Lambert-Eaton Myasthenia. CPT Pharmacometrics Syst Pharmacol. 2017 Jun 17. doi: 10.1002/psp4.12218. [Epub ahead of print] PMID: 28623849
154. Yang H, Enimil A, Gillani FS, Antwi S, Dompok A, Ortsin A, Awhireng EA, Owusu M, Wiesner L, **Peloquin CA**, Kwara A. Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children. Pediatr Infect Dis J. 2017 Jul 14. doi: 10.1097/INF.0000000000001687. [Epub ahead of print] PMID: 28719501
155. Alsultan A, Furin JJ, Du Bois J, van Brakel E, Chheng P, Venter A, Thiel B, Debanne SA, Boom WH, Diacon AH, Johnson JL, **Peloquin CA**. Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis. Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e01066-17. doi: 10.1128/AAC.01066-17. Print 2017 Oct. PMID: 28739794

A. Original research papers published in refereed journals (from 2009)

156. Bulman ZP, Chen L, Walsh TJ, Satlin MJ, Qian Y, Bulitta JB, **Peloquin CA**, Holden PN, Nation RL, Li J, Kreiswirth BN, Tsuji BT. Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era. *MBio*. 2017 Jul 25;8(4). pii: e00540-17. doi: 10.1128/mBio.00540-17. PMID: 28743810
157. Xu J, Tasneen R, Peloquin CA, Almeida DV, Li SY, Barnes-Boyle K, Lu Y, Nuermberger E. Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis. *Antimicrob Agents Chemother*. 2017 Oct 16. pii: AAC.01692-17. doi: 10.1128/AAC.01692-17. [Epub ahead of print] PMID: 29038265
158. Bouton TC, Phillips PPJ, Mitnick CD, **Peloquin CA**, Eisenach K, Patientia RF, Lecca L, Gotuzzo E, Gandhi NR, Butler D, Diacon AH, Martel B, Santillan J, Hunt KR, Vargas D, von Groote-Bidlingmaier F, Seas C, Dianis N, Moreno-Martinez A, Horsburgh CR Jr. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. *Trials*. 2017 Nov 25;18(1):563. doi: 10.1186/s13063-017-2292-x. PMID: 29178937
159. Heinrichs MT, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, Bablishvili N, Gogishvili S, Little BP, Bernheim A, Guarner J, **Peloquin CA**, Blumberg HM, Derendorf H, Kempker RR. Moxifloxacin target site concentrations in patients with pulmonary TB utilizing microdialysis: a clinical pharmacokinetic study. *J Antimicrob Chemother*. 2018 Feb 1;73(2):477-483. doi: 10.1093/jac/dkx421. PMID: 29186509
160. Dompok A, Tang X, Zhou J, Yang H, Topletz A, Adu Ahwireng E, Antwi S, Enimil A, Langae T, **Peloquin CA**, Court MH, Kwara A. Effect of genetic variation of NAT2 on isoniazid, SLCO1B1, and CES2 on rifampin pharmacokinetics in Ghanaian children with tuberculosis. *Antimicrob Agents Chemother*. 2017 Dec 20. pii: AAC.02099-17. doi: 10.1128/AAC.02099-17. [Epub ahead of print] PMID: 29263072
161. Kempker RR, Heinrichs MT, Nikolaishvili K, Sabulua I, Bablishvili N, Gogishvili S, Avaliani Z, Little BP, Bernheim A, Derendorf H, Blumberg HM, Vashakidze S, **Peloquin CA**. A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis. *Eur Respir J*. 2018 Feb 7;51(2). pii: 1702166. doi: 10.1183/13993003.02166-2017. Print 2018 Feb. PMID: 29437945
162. Weiner M, Gelfond J, Johnson-Pais TL, Engle M, **Peloquin CA**, Johnson JL, Sizemore EE, Mac Kenzie WR; Pharmacokinetics/Pharmacodynamics Group of Tuberculosis Trials Consortium. Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis. *Antimicrob Agents Chemother*. 2018 Feb 20. pii: AAC.01802-17. doi: 10.1128/AAC.01802-17. [Epub ahead of print] PMID: 29463526
163. Lyles G, Ogarkov O, Zhdanova S, **Peloquin CA**, Ebers A, Pfaeffle H, Al-Shaer MH, Moiseeva E, Zorkaltseva E, Koscheev M, Houpt ER, Heysell SK. Pharmacokinetics of tuberculosis drugs in HIV infected patients from Irkutsk, Russian Federation: redefining drug activity. *Eur Respir J*. 2018 Mar 29. pii: 1800109. doi: 10.1183/13993003.00109-2018. [Epub ahead of print] PMID: 29599189

A. Original research papers published in refereed journals (from 2009)

164. Alghamdi WA, Al-Shaer MH, **Peloquin CA**. Protein Binding of First-Line Antituberculosis Drugs. *Antimicrob Agents Chemother*. 2018 Jun 26;62(7). pii: e00641-18. doi: 10.1128/AAC.00641-18. Print 2018 Jul. PMID: 29735566
165. Drusano GL, Myrick J, Maynard M, Nole J, Duncanson B, Brown D, Schmidt S, Neely M, Scanga CA, **Peloquin C**, Louie A. Linezolid Kills Acid Phase and Non-replicative Persister Phase Mycobacterium tuberculosis in a Hollow Fiber Infection Model. *Antimicrob Agents Chemother*. 2018 Jun 4. pii: AAC.00221-18. doi: 10.1128/AAC.00221-18. [Epub ahead of print] PMID: 29866864
166. Heinrichs MT, May RJ, Heider F, Reimers T, B Sy SK, **Peloquin CA**, Derendorf H. Mycobacterium tuberculosis Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs. *Int J Mycobacteriol*. 2018 Apr-Jun;7(2):156-161. doi: 10.4103/ijmy.ijmy_33_18. PMID: 29900893
167. Horita Y, Alsultan A, Kwara A, Antwi S, Enimil A, Orstin A, Dompok A, Yang H, Wiesner L, **Peloquin CA**. Evaluation of the Adequacy of WHO revised Dosages of the First-Line Anti-Tuberculosis Drugs in Children with Tuberculosis using Population Pharmacokinetic Modeling and Simulations. *Antimicrob Agents Chemother*. 2018 Jun 18. pii: AAC.00008-18. doi: 10.1128/AAC.00008-18. [Epub ahead of print] PMID: 29914960
168. Velásquez GE, Brooks MB, Coit JM, Pertinez H, Vargas Vásquez D, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, **Peloquin CA**, Osso E, Tierney DB, Seung KJ, Lecca L, Davies GR, Mitnick CD. Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis: A Randomized Controlled Trial. *Am J Respir Crit Care Med*. 2018 Jun 29. doi: 10.1164/rccm.201712-2524OC. [Epub ahead of print] PMID: 29954183

XI. B. Review papers published in refereed journals (from 2009)

(total 39 papers: 13 first author, 14 senior author, 12 other)

22. Mitnick CD, McGee B, **Peloquin CA**. Tuberculosis pharmacotherapy: strategies to optimize patient care. *Expert Opin Pharmacother* 2009; 10: 381-401. PMID: 19191677
23. Sabarinath SN, Wu B, **Peloquin CA**, Derendorf H. Pharmacometrics in dose finding of anti-retroviral and anti-tubercular drugs. *Infect Disord Drug Targets*. 2011 Apr 1;11(2):157-66. PMID: 21406049
24. Egelund EF, Barth AB, **Peloquin CA**. Population Pharmacokinetics and its role in Anti-tuberculosis Drug Development & Optimization of Treatment *Curr Pharm Des*. 2011 Aug 12. [Epub ahead of print] PMID: 21834766
25. Seddon JA, Hesselting AC, Marais BJ, McIlleron H, **Peloquin CA**, Donald PR, Schaaf HS. Paediatric use of second-line tuberculosis agents: a review. *Tuberculosis (Edinb)*. 2011 Nov 24. [Epub ahead of print] PMID: 22118883
26. Lauzardo M, **Peloquin CA**. Anti-tuberculosis Therapy for 2012 and Beyond. *Expert Opin Pharmacother*. 2012; 13: 511-26.
27. Srivastava S, **Peloquin CA**, Sotgiu G and Migliori GB. Therapeutic Drug Management: is it the future of MDR-TB treatment? Letter. *European Respiratory Journal* 2013; 42:1449-1453.
28. Obeng AO, Egelund EF, Alsultan A, **Peloquin CA**, Johnson JA. CYP2C19 Polymorphisms and Voriconazole Therapy: Are We Ready for Clinical Implementation of Pharmacogenomics? *Pharmacotherapy*. 2014 Feb 7. doi: 10.1002/phar.1400. [Epub ahead of print] PMID: 24510446
29. Alsultan A, Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis, an update. *Drugs*. 2014; 74: 839-54. PMID: 24846578
30. Egelund EF, Fennelly KP, **Peloquin CA**. Medications and Monitoring in Nontuberculous Mycobacteria Infections. *Clin Chest Med*. 2015 Mar;36(1):55-66. doi: 10.1016/j.ccm.2014.11.001. Epub 2014 Dec 18.. PMID: 25676519
31. Egelund EF, Alsultan A, **Peloquin CA**. Optimizing the clinical pharmacology of tuberculosis medications. *Clin Pharmacol Ther*. 2015 Oct;98(4):387-93. doi: 10.1002/cpt.180. [Epub ahead of print] PMID: 26138226
32. Veringa A, Sturkenboom MGG, Dekkers BGJ, Koster RA, Roberts JA, **Peloquin CA**, Touw DJ, Alffenaar JWC. LC-MS/MS for Therapeutic Drug Monitoring of anti-infective drugs. *Trends in Analytical Chemistry* 2016; 84: 34–40
33. Lauzardo M, Peloquin CA. Tuberculosis therapy for 2016 and beyond. *Expert Opin Pharmacother*. 2016 Oct;17(14):1859-72. doi: 10.1080/14656566.2016.1215428. PMID: 27457206
34. Rifampentine for the treatment of latent tuberculosis. Egelund EF, Peloquin CA. *Expert Rev Clin Pharmacol*. 2016 Aug 22:1-9. [Epub ahead of print] PMID: 27545595

XI. B. Review papers published in refereed journals (from 2009)

35. Egelund EF, Dupree L, Huesgen E, **Peloquin CA**. The Pharmacological Challenges of Treating Tuberculosis and HIV Coinfections. *Expert Rev Clin Pharmacol*. 2016 Nov 9. [Epub ahead of print] PMID: 27828731
36. **Peloquin C**. The Role of Therapeutic Drug Monitoring in Mycobacterial Infections. *Microbiol Spectrum* 5(1):TNMI7-0029- 2016 doi: 10.1128/microbiolspec.TNMI7-0029-2016. PMID: 28084209
37. Alfarisi O, Alghamdi WA, Al-Shaer MH, Dooley KE, **Peloquin CA**. Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis? *Expert Rev Clin Pharmacol*. 2017 Oct;10(10):1027-1036. doi: 10.1080/17512433.2017.1366311. Epub 2017 Aug 18. Review. PMID: 28803492
38. Stott KE, Pertinez H, Sturkenboom MGG, Boeree MJ, Aarnoutse R, Ramachandran G, Requena-Méndez A, **Peloquin C**, Koegelenberg CFN, Alffenaar JWC, Ruslami R, Tostmann A, Swaminathan S, McIlleron H, Davies G. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. *J Antimicrob Chemother*. 2018 Apr 26. doi: 10.1093/jac/dky152. [Epub ahead of print] PMID: 29701775
39. Lange C, Alghamdi WA, Al-Shaer MH, Brighenti S, Diacon AH, DiNardo AR, Grobbel HP, Gröschel MI, von Groote-Bidlingmaier F, Hauptmann M, Heyckendorf J, Köhler N, Kohl TA, Merker M, Niemann S, **Peloquin CA**, Reimann M, Schaible UE, Schaub D, Schleusener V, Thye T, Schön T. Perspectives for personalized therapy for patients with multidrug-resistant tuberculosis. *J Intern Med*. 2018 May 28. doi: 10.1111/joim.12780. [Epub ahead of print] Review. PMID: 29806961

XI. C. Book Chapters (from 2009)

(total 44 chapters: 20 first author, 23 senior author, 1 other)

28. Namdar R, **Peloquin CA**. Ethionamide. In Yu VL, Edwards G, McKinnon PS, Peloquin C, Morse GD, editors. Antimicrobial Chemotherapy and Vaccines Vol II: Antimicrobial Agents 2010. Pittsburgh; Esun Technologies, LLC. Available from: <http://www.antimicrobe.org/index.asp>
29. **Peloquin CA**, Namdar R. Tuberculosis. In Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT Eds. Pharmacotherapy: principles and practice, 2nd Ed. McGraw Hill, New York, 2010. p 1253-1263.
30. **Peloquin CA**, Namdar R. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 8th ed. McGraw Hill, New York, 2011 p 1931-1949.
31. Egelund EF, **Peloquin CA**. Current Issues in Tuberculosis Pharmacokinetics. In Donald PR, van Helden PD, Eds. Antituberculosis Chemotherapy. Prog Respir Res. Basel, Karger, 2011, vol 40, pp 153–160.
32. Namdar R, **Peloquin CA**. Drugs for Tuberculosis. In Piscitelli SC, Rodvold KA, Pai MP Eds. Drug Interactions in Infectious Diseases, 3rd Edition. Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY, 2011, p 401-424.
33. Barth AB, Egelund EF, **Peloquin CA**. Rifamycin Use in HIV-infected Patients with Tuberculosis. Yi-Wei Tang, Ed. Recent Translational Research in HIV/AIDS. InTech, Rijeka, Croatia. 2011. ISBN 978-953-307-719-2
34. Namdar R, **Peloquin CA**. Tuberculosis. In PSAP VII Infectious Diseases, ACCP, Lenexa, KS 2012, p. 53-74.
35. **Peloquin CA**, Namdar R. Tuberculosis. In Chisholm-Burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, DiPiro JT Eds. Pharmacotherapy: principles and practice, 3rd Ed. McGraw Hill, New York, 2013, p 1315 – 1327.
36. Namdar R, Lauzardo M, **Peloquin CA**. Tuberculosis. In DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy: A pathophysiologic approach, 9th ed. McGraw Hill, New York, 2014, p 1787-1806.
37. Abdullah Alsultan, **Peloquin CA**. Clinical pharmacology of the anti-tuberculosis drugs. Davies PDO, Gordon SB, Davies G, Ed. Clinical Tuberculosis, 5th Ed. CRC Press, Boca Raton, 2014, p 209 – 228.
38. **Peloquin CA**. Pharmacometrics and Tuberculosis. In Derendorf H and Schmidt S, Eds. Applied Pharmacometrics. Springer New York, 2014, p 325-348.
39. Egelund EF, **Peloquin CA**. Antimycobacterial Drugs. In Lippincott's Illustrated Reviews: Pharmacology, 6th Edition. Wolters Kluwer 2015, p 525-534.

XI. C. Book Chapters (from 2009)

40. Barth AB, Egelund EF, **Peloquin CA**. Pharmacokinetics and Pharmacodynamics of the Tuberculosis Drugs. In John C. Rotschafer, David R. Andes, Keith A. Rodvold, Eds. Antibiotic Pharmacodynamics. Humana Press, Methods in Pharmacology and Toxicology, Springer Science+Business Media New York, 2016. ISBN: 978-1-4939-3321-1 (Print) 978-1-4939-3323-5 (Online) p 385-414.
41. Namdar R., Lauzardo M, **Peloquin CA**. Tuberculosis. In Chisholm-Burns MA, Schwinghammer TL, Wells BG, Malone PM, Rotschafer JC, DiPiro JT, Kolesar JM, Eds. Pharmacotherapy: principles and practice, 4th Edition. McGraw Hill, New York, 2016, p 1123-1134.
42. Namdar R, Lauzardo M, **Peloquin CA**. Tuberculosis. by Joseph T. DiPiro, Robert L. Talbert, Gary C. Yee, Gary R. Matzke, Barbara G. Wells, Eds. Pharmacotherapy: A pathophysiologic approach, 10th ed. McGraw Hill, New York, 2016, p 1779-2011.
43. **Peloquin CA**. The Role of Therapeutic Drug Monitoring. In Tuberculosis and Nontuberculous Mycobacterial Infections, 7th ed. Schlossberg D, editor. ASM Press, Herndon, VA, 2017, p 119-127.
44. Namdar R, **Peloquin CA**. Drugs for Tuberculosis. In Pai MP, Kiser JJ, Gubbins PO, Rodvold KA, Eds. Drug Interactions in Infectious Diseases: Antimicrobial Drug Interactions, 4th Edition. Humana Press, c/o Springer Science+Business Media, LLC, 233 Spring Street, New York, NY, 2018, p 221-253.

XI. D. Other Publications (from 2009)

(total 40 papers: 28 first author, 8 senior author, 4 other)

28. **Peloquin C.** Aminoglycoside nephrotoxicity. (letter) *Antimicrob Agents Chemother.* 2010; 54: 2750-2751. PMID: 20480959
29. Stein GE, Smith CL, **Peloquin CA**, Mosher B, Dybas L, Kepros JP. Bile and Gallbladder Tissue Concentrations of Moxifloxacin in Patients with Acute Cholecystitis. *Ann Pharmacother.* 2010 Jun 15. [Epub ahead of print] PMID: 20551298
30. **Peloquin CA** Pharmacokinetic Mismatch of Tuberculosis Drugs. *Antimicrob. Agents Chemother.* 2012, 56:1666.
31. Egelund EF**, **Peloquin CA.** Pharmacokinetic variability and TB treatment outcomes, including acquired drug resistance. Invited Editorial. *Clin Infect Dis.* 2012 Jul;55(2):178-9. doi: 10.1093/cid/cis366. Epub 2012 Mar 30. PMID: 22467672
32. Nuermberger EL, Rosenthal IM, Tasneen R, **Peloquin CA**, Mdluli KE, Karakousis PC, Grosset JH. Reply to "contradictory results with high-dosage rifamycin in mice and humans". *Antimicrob Agents Chemother.* 2013 Feb;57(2):1104-5. doi: 10.1128/AAC.02216-12. PMID: 23341430
33. Egelund EF, Mohamed M, Fennelly KP, **Peloquin CA.** Concomitant Use of Carbamazepine and Rifampin in a Patient with Mycobacterium Avium Complex and Seizure Disorder. *Journal of Pharmacy Technology* 2014; 30: 93-96.
34. **Peloquin CA.** Pharmacometrics in Tuberculosis. In Derendorf H and Schmidt S, Eds. Henry Stewart Talks. http://hstalks.com/main/view_talk.php?t=2953&r=494&c=252 December 2014
35. **Peloquin CA**, Dorman SE, Vernon A, Battista Migliori G, Nahid P. Reply to Alffenaar et al. *Clin Infect Dis.* 2016 Oct 26. pii: ciw679. [Epub ahead of print] PMID: 27789610
36. Egelund EF, Dupree L, Huesgen E, **Peloquin CA.** The Pharmacological Challenges of Treating Tuberculosis and HIV Coinfections. *Expert Rev Clin Pharmacol.* 2016 Nov 9. [Epub ahead of print] PMID: 27828731
37. Abdullah Alsultan, **Charles A. Peloquin** Pharmacokinetics and pharmacodynamics of isoniazid in patients with intermediate resistance. *Int J Tuberc Lung Dis.* 2017 Jan 1;21(1):121-123. doi: 10.5588/ijtld.16.0689. PMID: 28157477
38. Kempker RR, **Peloquin CA**, Blumberg HM, Vashakidze S. *Antimicrob Agents Chemother.* Reply to Srivastava et al., "pH Conditions under Which Pyrazinamide Works in Humans". 2017 Aug 24;61(9). pii: e01120-17. doi: 10.1128/AAC.01120-17. Print 2017 Sep. No abstract available. PMID: 28839080
39. **Peloquin CA**, Kempker RR. Reply to Chang et al., "Pyrazinamide Is a Two-Edged Sword: Do WHO Guidelines Matter?" *Antimicrob Agents Chemother.* 2017 Dec 21;62(1). pii: e01937-17. doi: 10.1128/AAC.01937-17. Print 2018 Jan. PMID: 29269429
40. Alffenaar JWC, **Peloquin CA**, Migliori GB. Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone. *Int J Tuberc Lung Dis.* 2018 Jan 1;22(1):2. doi: 10.5588/ijtld.17.0632. PMID: 29297417

XI. E. Abstracts (from 2009)

(total 151 abstracts; 29 first author, 35 senior author, 87 other)

74. Weiner M, **Peloquin C**, Burman W, Luo CC, Engle M, Prihoda T, Mac Kenzie W, Bliven E, Johnson J, Vernon A for the Tuberculosis Trials Consortium. The effects of tuberculosis infection, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Abstract 1, 2nd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, San Francisco, CA, September 11, 2009.
75. Ahmad Z, **Peloquin C**, Tyagi S, Grosset JH, Nuermberger EL. PA-824 has time-dependent bactericidal activity in a murine model of tuberculosis. Abstract 4, 2nd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, San Francisco, CA, September 11, 2009.
76. **Peloquin C**. PK-PD mismatch in TB drug regimens. Abstract 12, 2nd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, San Francisco, CA, September 11, 2009.
77. Almeida D, Nuermberger EL, Tasneen R, Rosenthal I, Tyagi S, **Peloquin C**, Grosset JH. Paradoxical effect of isoniazid on the activity of the rifampin-pyrazinamide combination in the mouse model of tuberculosis. 2nd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, San Francisco, CA, September 11, 2009.
78. Ahmad Z, **Peloquin C**, Tyagi S., J.H. Grosset., E. L. Nuermberger. Pa-824 Exhibits Time-Dependent Bactericidal Activity in a Murine Tuberculosis Model. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (A1-607), San Francisco, CA, September 12-15, 2009.
79. Curtis L. Smith, Gary E. Stein, Benjamin Mosher, **Charles Peloquin**, Leslie A. Dybas, and John P. Kepros. Bile and gallbladder tissue concentrations of moxifloxacin in patients with infectious cholecystitis for presentation at the 2010 Spring Practice and Research Forum (April 23-27), Charlotte, NC.
80. Ahmad Z, **Peloquin CA**, Minkowski A, Grosset JH and Nuermberger EL. The anti-tuberculous activity of pyrazinamide is driven by AUC/MIC in murine tuberculosis. 3rd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.
81. Ahmad ., **Peloquin CA**, Minkowski A, Ginsberg A, Grosset JH and Nuermberger EL. PA-824 exhibits time-dependent bactericidal activity against persisting Mycobacterium tuberculosis. 3rd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.
82. Ahmad Z, Pinn ML, Tyagi S, **Peloquin CA**, Nuermberger EL, Grosset JH, and Karakousis PC. Towards a guinea pig model for preclinical TB drug testing. 3rd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.
83. **Peloquin C**, Weiner M, Engel M, Johnson H, Nsubuga P, Bliven E, Padayatchi N, Mthethwa T, MacKenzie W. Pharmacokinetics of rifapentine in TB patients receiving 600 mg daily. 3rd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.
84. **Peloquin C**, Jereb J, Daley C, Fred D, Mase S. The pharmacokinetics of moxifloxacin in MDR TB contacts in the Federated States of Micronesia. 3rd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.

XI. E. Abstracts

85. **Peloquin C**, Jereb J, Daley C, Fred D, Mase S. The pharmacokinetics of levofloxacin in MDR TB contacts in the Federated States of Micronesia. 3rd International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Boston, MA, Sep. 11, 2010.
86. Ahmad Z, Pinn M, Tyagi S, **Peloquin C**, Nuernberger E, Grosset J, Karakousis PC. Do Caseating Granulomas Interfere with the Sterilizing Activity of the Standard Antituberculous Regimen? 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, Sep. 12-15, 2010. Abstract B-2010.
87. Ahmad Z., **Peloquin CA**, Minkowski A., Grosset JH and Nuernberger EL. The anti-tuberculous activity of pyrazinamide is driven by AUC/MIC in murine tuberculosis. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, Sep. 12-15, 2010.
88. E. Nuernberger, Z. Ahmad, Tyagi S., Ginsberg A, J.H. Grosset, **Peloquin C**. Pharmacodynamics of PA-824 activity in murine TB. IUATLD Berlin November 11-15 2010.
89. Jenna A. Rhoades, Hao-Jie Zhu, David I. Appel, Yuri K. Peterson, **Charles A. Peloquin** and John S. Markowitz. An *in-vitro* Evaluation of Protease Inhibitors on Carboxylesterase 1: A Potential Source of Drug-Drug Interactions. 24th Annual Research Showcase and Awards Recognition Day, February 17th, 2011
90. M. Weiner, **C. Peloquin**, E. Egelund, M. Engle, E. Bliven-Sizemore, W. R. Mac Kenzie, J. L. Johnson, P. Nsubuga, T. J. Prihoda, S. Dorman, W. J. Burman. Rifapentine Exposure In A Trial Of Daily Rifapentine Compared To Rifampin During The Intensive Phase Of TB Treatment. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado
91. J.H.E. Grosset, M. Zhang, S.-Y. Li, **C. Peloquin**, D. Almeida, S. Tyagi, P. Converse, E.L. Nuernberger. In Contrast To Isoniazid, Ethambutol Does Not Antagonize The Rifampin - Pyrazinamide Combination. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado
92. J. van Ingen, S. Totten, L.B. Heifets, **C. Peloquin**, C. L. Daley. Drug Susceptibility Testing And Pharmacokinetics Question Current Treatment Regimens In Mycobacterium Simiae Complex Disease. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado
93. S. R. Mase, J. Jereb, C.L. Daley, D. Fred, A. Loeffler, **C. Peloquin**. Pharmacokinetics Of Levofloxacin In Pediatric Mdr Tb Cases And Contacts, Federated States Of Micronesia. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado
94. S. R. Mase, J. Jereb, C. L. Daley, D. Fred, A. Loeffler, **C. Peloquin**. The Pharmacokinetics Of Moxifloxacin In Mdr Tb Cases And Contacts, Federated States Of Micronesia. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado
95. J. van Ingen, A. Levin, S. Totten, L. B. Heifets, **C. Peloquin**, C. L. Daley. Pharmacokinetics And Drug Susceptibility Testing Imply Limited Activity Of Current Regimens For Mycobacterium Avium Complex Disease. American Thoracic Society 2011 International Conference, May 13-18, 2011, Denver, Colorado

XI. E. Abstracts

96. Glover, T. L., Goodin, B. R., Kindler, L. L., King, C. B., Sibille, K., Horgas, A. L., **Peloquin, C**, Riley, III, J. R., Staud, R., Bradley, L. A., & Fillingim, R. B. (2011, May). Vitamin D deficiency as a mediator of ethnic differences in experimental pain: preliminary findings. Poster session to be presented at the meeting of the American Pain Society, May 18-21, 2011, Austin, TX.
97. Barth AB, Singh RP, Egelund EF, Ahmad Z, Nuermberger EL, **Peloquin CA**, Derendorf H. Exploratory pharmacokinetics – pharmacodynamics (PK-PD) target attainment analysis of PA-824. 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Chicago, IL, Sep. 16, 2011.
98. Nuermberger EL, Tanseen R, Li S, **Peloquin C**, Andries K, Mdluli K, Grosset J. Novel TMC-207-containing regimens have sterilizing activity in murine tuberculosis. 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Chicago, IL, Sep. 16, 2011.
99. **Peloquin C**, Weiner M, Bliven-Sizemore E, Egelund E, Engle M, Johnson J, Nsubuga P, MacKenzie WH. Modeling the pharmacokinetics of rifapentine in TB patients receiving 10 mg/kg daily. 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Chicago, IL, Sep. 16, 2011.
100. Marc Weiner, **Charles Peloquin**, Melissa Engle, Eric Egelund, Thomas Prihoda, William Mac Kenzie. The Pharmacokinetic Interaction Between Raltegravir and Rifapentine in Healthy Volunteers. 1th Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, March 5-8, 2012.
101. M Degroote; J Gilliland; E Brooks; E Driver; R Basaraba; **C Peloquin**; I Orme; A Lenaerts. Evaluation of Linezolid in Mice Infected with Mycobacterium tuberculosis. Drug Resistance and Persistence in Tuberculosis, Kampala, Uganda, May 13 - May 18, 2012
102. S. R. Mase, J. Jereb, F. Martin, C. L. Daley, D. Fred, K. Briand, A. Loeffler, S. Bamrah, R. Brostrom, **C. Peloquin**, T. Chorba. Pharmacokinetics Studies of Levofloxacin in Children Treated for, or Exposed to, Multidrug-Resistant Tuberculosis — United States Affiliated Pacific Islands, 2010–2011. American Thoracic Society 2012 International Conference, May 18-23, 2012, San Francisco, CA
103. R.M. Savic, M. Weiner, W. Mac Kenzie, E. Bliven-Sizemore, **C.A. Peloquin**, K. Dooley, S.M. Abdel-Rahman, G.L. Kearns, W. Burman, T.R. Sterling, M.E. Villarino, and the Tuberculosis Trials Consortium. Population pharmacokinetics of once weekly rifapentine in children and adults. 5th International workshop on Clinical Pharmacology of TB Drugs, San Francisco, CA, USA, 8 September 2012
104. M. Weiner, R. Savic, D. Wing, W.R. Mac Kenzie, **C.A. Peloquin**, M. Engle, E. Bliven, A. Borisov, S.M. Abdel-Rahman, G.L. Kearns, W. Burman, T.R. Sterling, M.E. Villarino and the Tuberculosis Trials Consortium Study 26PK Group. Rifapentine Pharmacokinetics and Tolerability in Children and Adults Treated Once Weekly with Rifapentine/Isoniazid for Latent Tuberculosis Infection. 5th International workshop on Clinical Pharmacology of TB Drugs, San Francisco, CA, USA, 8 September 2012.
105. Pinn ML, Dutta NK, Sultan A, **Peloquin CA** and Karakousis PC. Comparative pharmacokinetics of repeated doses of rifampin and rifapentine in guinea pigs. Host Response in Tuberculosis, January, 2013• British Columbia, Canada.

XI. E. Abstracts

106. Barth A, Singh R, Brull N, Reljac K, Klopp-Schulze L, **Peloquin C**, Derendorf, H. PK-PD Evaluation of Levofloxacin in vitro- Preliminary Data. Presented during the 26th College of Pharmacy Annual Research Showcase, Gainesville, FL. Feb/2013

107. Eric F. Egelund, R.P. Singh, Behrang Mahjoub, Hartmut Derendorf, Marc Weiner, **Charles A. Peloquin**. Protein Binding of Rifapentine and Its Metabolite, 25-desacetyl Rifapentine, in Patients with Pulmonary Tuberculosis. Emerging Pathogens Institute, University of Florida. Gainesville, FL. February 2013.

108. Daniel Gonzalez, Sundari Mase, John Jereb, F.S. Martin, Charles Daley, Dorina Fred, K. Briand, Ann Loeffler, Sapna Bamrah, K. Powell, Richard Brostrom, Terry Chorba, **Charles Peloquin**. Population Pharmacokinetics of Levofloxacin in Children Treated for, or Exposed to, Multidrug Resistant Tuberculosis in the Federated States of Micronesia and Republic of Marshall Islands. American Conference on Pharmacometrics, May 12-15, 2013 in Fort Lauderdale, FL

109. Abdullah Alsultan, Kelly E. Dooley, Marc Weiner, William Whitworth, William R. Mac Kenzie, **Charles A. Peloquin** and the Tuberculosis Trials Consortium. Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. American Conference on Pharmacometrics, May 12-15, 2013 in Fort Lauderdale, FL

110. Dutta NK, Belchis D, **Peloquin C**, Nuernberger EL, Mdluli K and Karakousis PC. Dramatic efficacy of the novel three-drug regimen PaMZ (PA-824/moxifloxacin/pyrazinamide) against chronic tuberculosis infection in guinea pigs. American Thoracic Society International Conference. May 17, 2013• Philadelphia, USA.

111. Aline Barth, Ravi Singh, **Charles Peloquin** and Hartmut Derendorf. Microdialysis as a tool to measure antimicrobials in the lung tissue – in vivo and ex vivo considerations. 7th Microdialysis Symposium - Université de Poitiers, France, May 23-24, 2013.

112. Awewura Kwara, Margaret Lartey, Ernest Kenu, Behrang Mahjoub, **Charles Peloquin**. Isoniazid, rifampicin and pyrazinamide pharmacokinetics in Ghanaian HIV/Tuberculosis Co-infected patients. 44th Union World Conference on Lung Health in Paris, France, November 2, 2013

113. D. Gonzalez, S. Mase, J. Jereb, F. Martin, C. Daley, D. Fred, K. Briand, A. Loeffler, T. Chorba, **C. Peloquin**. Population pharmacokinetics of levofloxacin in children treated for multidrug resistant tuberculosis. 6th International Workshop on Clinical Pharmacology of TB drugs, Denver, CO, Sept 9, 2013.

114. A. Alsultan, K. Dooley, M. Weiner, W. Whitworth, W. Mac Kenzie, **C. Peloquin**. Clinical Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis. 6th International Workshop on Clinical Pharmacology of TB drugs, Denver, CO, Sept 9, 2013.

115. Savic RM, Weiner M, MacKenzie W, Helig C, Dooley K, Engle M, Nsubuga P, Phan H, **Peloquin C**, Dorman S. PK PD analysis of rifapentine in patients during intensive phase treatment for tuberculosis from Tuberculosis Trial Consortium Studies 29 and 29X. 6th International Workshop on Clinical Pharmacology of TB drugs, Denver, CO, Sept 9, 2013.

XI. E. Abstracts

116. Brock, AP, Isaza R, Egelund, EF, Hunter, **Peloquin CA**. Pharmacokinetics of a single oral or rectal dose of concurrently administered isoniazid, rifampin, pyrazinamide and ethambutol in Asian elephants (*Elephas maximus*) 45th American Association of Zoo Veterinarian Annual Conference, Sept 28-Oct 4, 2013, Salt Lake City, UT.
117. Barth A, Singh R, May J, Johnson J, Prieto E, Isaza R, Kempker R, **Peloquin C**, Derendorf H. Levofloxacin Dose Optimization for Multidrug Resistant Tuberculosis Based on Lung Microdialysis in Patients. Presentation during two meetings: 27th Annual Research Showcase, Gainesville, FL; and EPI Research Day 2014, Gainesville, FL. Feb/2014 Feb/2014
118. Eric F. Egelund, A. Paige Brock, Ramiro Isaza, Robert P. Hunter, **Charles A. Peloquin**. The Pharmacokinetics of a Single Oral or Rectal Dose of Concurrently Administered Isoniazid, Rifampin, Pyrazinamide, and Ethambutol in Asian Elephants (*Elephas maximus*). Emerging Pathogens Institute, University of Florida. Gainesville, FL. February 2014.
119. Sara H Browne, Richard Haubrich, Heather McClendon*, Lorenzo DiCarlo, **Charles Peloquin**, Kathleen Moser, Constance Benson Wirelessly Observed Therapy (WOT) Compared to Directly Observed Therapy (DOT) for the Treatment of TB. National TB Conference (NTCA) 2014, Atlanta, GA, June 11-13.
120. Aline Barth, Ravi Shankar P. Singh, Robert May, Judith Johnson, Ramiro Isaza, Henry Michael Blumberg, Sergo Vashakidze, **Charles Peloquin**, Hartmut Derendorf, Russell Kempker. Levofloxacin Dose Optimization for Multidrug-resistant Tuberculosis Based on Lung Microdialysis in Patients. American College of Clinical Pharmacology annual meeting September 14th–16th 2014, Atlanta, Georgia
121. A. Alsultan, Derby R, An G, **C.A. Peloquin**. Bayesian Estimation of Levofloxacin Pharmacokinetics in Patients with Tuberculosis. 2 meetings: 7th International Workshop on Clinical Pharmacology of TB drugs, Washington, DC, Sept 5, 2014 and Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 5-9, 2014.
122. Horsburgh CR, Phillips PPJ, Mitnick CM, Diacon A, Gotuzzo E, Lecca L, Eisenach K, Dianis, N, Drusano G, **C. Peloquin**. Efficient Study Design to Determine optimal Drug Dosing for MDR-TB. 7th International Workshop on Clinical Pharmacology of TB drugs, Washington, DC, Sept 5, 2014.
123. A. Alsultan, Mendez M, **C.A. Peloquin**. Therapeutic Drug Monitoring of Second Line Tuberculosis Drugs. 7th International Workshop on Clinical Pharmacology of TB drugs, Washington, DC, Sept 5, 2014.
124. I. Zentner, L. Khensouvann, M. Kutzler, H. Schlecht, G.P. Bisson, **C. Peloquin**, C. Vinnard. A Urine Colorimetric Assay to Detect Low Peak Serum Concentrations of Pyrazinamide: A Proof-of-Concept Study. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 5-9, 2014.
125. W. W. Hope , T. J. Walsh, J. Goodwin, **C. Peloquin**, A. Howard, J. Kurtzberg, A. Menizabal, D. Confer, J. Bulitta, M. Neely, L. Baden, J. Wingard. Relationship Between Voriconazole Concentrations and the Probability of Breakthrough Fungal Infections. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 5-9, 2014.

XI. E. Abstracts

126. N. Bannietis , R. Sharma, I. Hand, **C. Peloquin**, K. Stephan, H. R. Margaret. Steady State Pharmacokinetics of Linezolid (LZ) Suspension in Premature Infant with Osteomyelitis. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 5-9, 2014.
127. Lorna Khensouvann, Michele Kutzler, Tawanda Gumbo, Jotam Pasipanodya, Hans Schlecht, Gregory P. Bisson, **Charles Peloquin**, Christopher Vinnard. Urine Colorimetry to Detect Low Rifampicin Bioavailability: A Proof-of-Concept Study. 45th Union World Conference on Lung Health, 2014.
128. Sara Browne*, Richard Haubrich, Constance Benson, Kathleen Moser, Lorenzo DiCarlo, **Charles Peloquin**. Wirelessly Observed Therapy (WOT): A New Paradigm in TB Therapy Monitoring. Conference on Retrovirus and Opportunistic Infections (CROI) 2015, Seattle, Washington, February 23-26, 2015
129. Tobias Heinrichs, Robert May, Russell Kempker, Judith Johnson, **Charles Peloquin**, Hartmut Derendorf. Moxifloxacin and Pyrazinamide Dose Optimization for Multidrug-resistant and Extensively Drug-resistant Tuberculosis Annual Meeting of the American College of Clinical Pharmacology, September 27–29, 2015, San Francisco, CA
130. Alyshia Wiggins, Abdullah Alsultan, **Charles Peloquin**. Therapeutic Drug Monitoring of Ethambutol in Patients with Tuberculosis. 8th Workshop on Clinical Pharmacology of TB drugs, San Diego, CA, September 17, 2015
131. E Harausz, J Leigh, TJ Zagurski, J Furin, **CA Peloquin**. Stability of Second-Line Tuberculosis Drugs Mixed with Readily Available, Nutritious Foods. 8th Workshop on Clinical Pharmacology of TB drugs, San Diego, CA, September 17, 2015
132. A. Sultan, B. Mahjoub, **C.A. Peloquin**. Determining protein binding of levofloxacin and moxifloxacin in vitro using ultrafiltration. 8th Workshop on Clinical Pharmacology of TB drugs, San Diego, CA, September 17, 2015
133. S. Browne, R. Haubrich, K. Moser, **C. Peloquin**, L. di Carlo, C. Benson. Digitizing MTB Medicines: Using compounding methods to enable mobile capture of MTB medication adherence. 8th Workshop on Clinical Pharmacology of TB drugs, San Diego, CA, September 17, 2015
134. A. Alsultan, J. Furin, J. Du Bois, E. van Brakel, P. Chheng, A. Venter, B. Thiel, S. Debanne, W. Henry Boom, A. Diacon, J. Johnson, **C. Peloquin**. Population Pharmacokinetics of AZD5847 in Adults with Pulmonary Tuberculosis. 9th Workshop on Clinical Pharmacology of TB drugs, Liverpool, UK October 24, 2016.
135. **Peloquin CA**, Mitnick CD, Lecca L, Calderon R, Coit J, Milstein M, Osso E, Jimenez J, Tintaya K, Sanchez Garavito E, Vargas Vasquez D, Davies G. Optimizing the Dose of Rifampin: Pharmacokinetic Results from the HIRIF Trial. 9th Workshop on Clinical Pharmacology of TB drugs, Liverpool, UK October 24, 2016.
136. Henry M. Blumberg, **Charles Peloquin**, Taylor Foreman, Smriti Mehra, Jyothi Rengarajan, Deepak Kaushal; and the TBRU ASTRa Study Group. Rifapentine plus Isoniazid Eradicates Mycobacterium tuberculosis among Rhesus Macaques with Latent TB Infection. 9th Workshop on Clinical Pharmacology of TB drugs, Liverpool, UK October 24, 2016.

XI. E. Abstracts

137. Ebers, O. Ogarkov, S. Zhdanova, H. Pfaeffle, **C. Peloquin**, S. Heysell. Isoniazid and Levofloxacin pharmacokinetics and outcomes in a Russian cohort with Human Immunodeficiency Virus and Tuberculosis 9th Workshop on Clinical Pharmacology of TB drugs, Liverpool, UK October 24, 2016.
138. Russell R. Kempker, Marc Tobias Heinrichs, Ketino Nikolaishvili, Irina Sabulua, Nestani Tukvadze, Nino Bablishvili, Shota Gogishvili, Brent Little, Adam Bernheim, Jeannette Guarner, Hartmut Derendorf, **Charles A. Peloquin**, Henry M. Blumberg, Sergo Vashakidze. Lung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis. 9th Workshop on Clinical Pharmacology of TB drugs, Liverpool, UK October 24, 2016.
139. Radojka Savic; **Charles Peloquin**; Martin Boeree; Marc Weiner; Norbert Heinrich; Erin Bliven-Sizemore; William Whitworth; Glenn Morlock; James Posey; William Mac Kenzie; Robert Aarnoutse; Kelly E. Dooley. The relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS. 9th Workshop on Clinical Pharmacology of TB drugs, Liverpool, UK October 24, 2016.
140. Awewura Kwara, Hongmei Yang, Anthony Enimil, Fizza S. Gillani, Albert Dompok, Antoinette Orsin, Lubbe Wiesner, **Charles A Peloquin**, Sampson Antwi. Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children 20th Conference of The Union Africa Region, Accra- Ghana, 10-13 July, 2017
141. Sara H. Browne, Kathleen Moser, Julie Low, Florin Vaida, Amanda J. Tucker, J Gonzalez-Garcia, **Charles A. Peloquin**, Constance A. Benson. WIRELESSLY OBSERVED THERAPY IS ACCURATE AND CONFIRMS MORE TB MEDICATION DOSES THAN DIRECTLY OBSERVED THERAPY. Union World Conference on Lung Health, October 11-14, 2017. Guadalajara, Mexico.
142. R Kempker, MT Heinrichs, I Sabulua, N Bablishvili, H Derendorf, H Blumberg, S Vahakidze, **C Peloquin**. Lunch tissue concentrations of linezolid among patients with drug-resistant tuberculosis. Union World Conference on Lung Health, October 11-14, 2017. Guadalajara, Mexico.
143. C Boulanger, V Rolla, **C.Peloquin**. A pharmacokinetic study of super-boosted lopinavir/ritonavir in combination with rifampin in HIV-1 infected patients with tuberculosis. Union World Conference on Lung Health, October 11-14, 2017. Guadalajara, Mexico.
144. **Charles A. Peloquin**, Patrick P.J. Phillips, Carole D. Mitnick, Kathleen Eisenach, Ramonde F. Patientia, Leonid Lecca, Eduardo Gotuzzo, Neel R. Gandhi, Donna Butler, Andreas H. Diacon, Bruno Martel, Juan Santillan, Kathleen Robergeau Hunt, Dante Vargas, Florian von Groote-Bidlingmaier, Carlos Seas, Nancy Dianis, Antonio Moreno-Martinez, C. Robert Horsburgh Jr. Optimizing the Dose of Levofloxacin: Pharmacokinetic Results from the Opti-Q Study. 10th International workshop on Clinical Pharmacology of TB Drugs, Sunday 15 October 2017, Atlanta, USA

XI. E. Abstracts

145. Mohammad H. Al-Shaer, Yosra Alkabab, Stellah G. Mpagama, Anna Cholongu, Buliga Mujaga, Jean Gratz, Eric R. Houpt, **Charles Peloquin**, Scott K. Heysell. Ototoxicity is associated with exposure to kanamycin and capreomycin in the treatment of multidrug-resistant tuberculosis. 10th International workshop on Clinical Pharmacology of TB Drugs, Sunday 15 October 2017, Atlanta, USA
146. Abdullah Alsultan, Michael Neely, Wael Alghamdi, Mohammad Alshaer, Scott K. Heysell, Russell R. Kempker, Stellah G. Mpagama, Maia Kipiani, Anna Chongolo, Eric R. Houpt, Guohua An, **Charles Peloquin**. Population Pharmacokinetics of Cycloserine. 10th International workshop on Clinical Pharmacology of TB Drugs, Sunday 15 October 2017, Atlanta, USA
147. Wael A. Alghamdi, Ketevan Barbakadze, Yasuhiro Horita, Maia Kipiani, Russell Kempker, **Charles A. Peloquin**. Pharmacokinetics of Bedaquiline and Delamanid in Patients with MDR-TB. 10th International workshop on Clinical Pharmacology of TB Drugs, Sunday 15 October 2017, Atlanta, USA
148. H Pertinez, **CA Peloquin**, GE Velásquez, L Lecca, RI Calderón, J Coit, M Brooks, E Osso, J Jimenez, K Tintaya, E Sanchez Garavito, D Vargas Vasquez, CD Mitnick, G Davies. Population Pharmacokinetics of Rifampin in the HIRIF clinical trial. 10th International workshop on Clinical Pharmacology of TB Drugs, Sunday 15 October 2017, Atlanta, USA
149. Gustavo E. Velásquez, Meredith B. Brooks, Julia M. Coit, Dante Vargas Vásquez, Epifanio Sánchez Garavito, Roger I. Calderón, Judith Jiménez, Karen Tintaya, **Charles A. Peloquin**, Elna Osso, Dylan B. Tierney, Kwonjune J. Seung, Leonid Lecca, Geraint R. Davies, Carole D. Mitnick. A RANDOMIZED CONTROLLED TRIAL OF HIGH-DOSE RIFAMPIN FOR PULMONARY TUBERCULOSIS. CROI, Boston, Massachusetts, March 4–7, 2018
150. Sara H. Browne, **Charles A. Peloquin**, Amanda J. Tucker, Kathleen Moser, Julie Low, Anya Umlauf, Florin Vaida, Constance A. Benson. WIRELESSLY OBSERVED THERAPY VS DIRECTLY OBSERVED THERAPY FOR TB MEDICATION ADHERENCE. CROI, Boston, Massachusetts, March 4–7, 2018
151. Awewura Kwara, Hongmei Yang, Sampson Antwi, Anthony Enimil, Fizza S. Gillani, Anima M. Sarfo, Antoinette Orsin, Albert Dompok, Lubbe Wiesner, **Charles A. Peloquin**. EFFECT OF ANTITUBERCULOSIS THERAPY ON THE PHARMACOKINETICS OF EFAVIRENZ IN CHILDREN. CROI, Boston, Massachusetts, March 4–7, 2018

XI. F. Presentations at Scientific Meetings (from 2009)

F. 1. Invited International Lectures

31. Symposium: Important new dosage regimens for TB: New PK understanding. Infectious Disease Society of America. Philadelphia, PA November 1, 2009
32. Symposium: TB / HIV Update: Drug-Drug Interactions. International Union Against TB and Lung Disease, North American Region. March 11, 2010, Orlando, FL
33. Drug Interactions. Forum to Promote TRIUMPH: TB Research in Underserved Maternal and Pediatric Populations with HIV. July 29-30, 2010 Bethesda, MD
34. Studying PK/PD of TB drugs - A daunting challenge. International Society of Anti-Infective Pharmacology Post-ICAAC Symposium, Wednesday, September 15th, 2010, Boston, MA
35. Anti-Mycobacterial Drugs. Infectious Disease Society of America (IDSA) 48th Annual Meeting, October 21-24, 2010, Vancouver, BC, Canada
36. Pharmacokinetics of Antituberculosis Agents: Current Issues. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2011, Chicago, IL.
37. Pharmacodynamics, Drug interactions, Intolerance and Toxicity of TB drugs. Haiti's National strategies for universal treatment and prevention of tuberculosis: development of policies and guidelines for MDR TB diagnosis and treatment. Ministere de la Sante Publique et de la Population, Petion-Ville, Haiti July 2 – 3, 2012
38. Population pharmacokinetics of TB drugs are predictable. Scientific meeting MDR-TB. Pharmacokinetics: individually or population-wise? Wenckebach Instituut, University Center of Rehabilitation, Beatrixoord, ND Haren, The Netherlands, March 8, 2013.
39. Accounting for Variability: Pharmacokinetics in TB Treatment. Gordon research Conference: Tuberculosis Drug Development. Renaissance Tuscany Il Ciocco Resort in Lucca (Barga) Italy, July 25, 2013.
40. Pharmacokinetic Variability and Tuberculosis Treatment Outcomes. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, Sept 5-9, 2014.
41. Update on Multidrug Resistant Tuberculosis. ACCP Annual Meeting, 2014, Austin, TX, October 12-15.
42. Individualized Antibiotic Therapy. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA, Sept 17-21, 2015.
43. Validation of assays for TDM, from clinical research to clinical practice (recorded). Therapeutic Drug Monitoring (TDM) Workshop, April 1, 2016, Tan Tock Seng Hospital and National University Hospital, Singapore
43. Rifampin versus Rifapentine. 9th Workshop on Clinical Pharmacology of TB drugs, Liverpool, UK October 24, 2016.

XI. F. Presentations at Scientific Meetings (from 2009)
F. 1. Invited International Lectures (continued)

44. Therapeutic Drug Monitoring (TDM). Technical Expert consultation on critical concentrations and clinical cut-offs for drug susceptibility testing of second-line TB medicines. World Health Organization, 24-26 April, 2017, Geneva, Switzerland.
45. Linezolid. Technical Expert consultation on critical concentrations and clinical cut-offs for drug susceptibility testing of second-line TB medicines. World Health Organization, 24-26 April, 2017, Geneva, Switzerland.
46. Dosing of Anti-Tuberculosis Drugs Facilitated by Understanding PK-PD. ASM Microbe, June 1-5, 2017, New Orleans, LA
47. TDM of Anti-Tuberculosis Medications. IATDMCT Congress Sep. 24-27, 2017, Kyoto, Japan
48. TDM of Anti-Tuberculosis Medications. Japanese Anti-TB Association, Sep. 28, 2017, Tokyo, Japan

XI. F. Presentations at Scientific Meetings (from 2009)

F. 2. Invited National Lectures

10. Pharmacokinetics 101.

CDC Tuberculosis Clinical Trial Consortium (TBTC) Study Coordinators Meeting, Atlanta GA, October 17, 2007 South Eastern TB Controllers Meeting, Biloxi, MS, October 20, 2009

11. MDR-TB: An Update on Treatment Options and Management.

ACCP Annual Meeting, Louisville, KY, October 21, 2008.

12. Pharmacokinetics & Pharmacodynamics: Why Do TB Drugs Fail?

Southeastern National TB Center (SNTC) National Webinar: Grand Rounds – Wednesday, October 7, 2009, 11:00 a.m. - 12:30 p.m. EDT

13. TB and HIV, Clinical Challenges and New Solutions.

UF COP National Advisory Board meeting, November 6, 2009, Gainesville, FL

14. Pharmacokinetics and Pharmacodynamics in the treatment of TB. National TB Conference,

National Society of TB Clinicians Annual Meeting, Atlanta, GA, June 21, 2010.

15. Drug-drug interactions: What to keep on your radar. Common culprits and newer agents. National TB Conference, National Society of TB Clinicians Annual Meeting, Atlanta, GA, June 13, 2011.

16. The Role of Therapeutic Drug Monitoring. 6th Annual TB Medical Consultant's Meeting, New Jersey National TB Center, Newark, NJ, November 7-8, 2012.

17. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, December 4, 2012.

18. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, October 9, 2013.

19. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, December 11, 2013.

20. Therapeutic Drug Monitoring: Nuts and Bolts. Southeastern National TB Center (SNTC) Webinar, Gainesville, FL, January 29, 2014.

21. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, March 5, 2014.

22. Therapeutic Drug Monitoring: Nuts and Bolts. 2014 World TB Day Symposium: New Challenges and New Tools in the Diagnosis and Management of Tuberculosis, Vanderbilt University, Nashville, TN, April 1, 2014.

23. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, October 8, 2014.

24. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, December 10, 2014.
25. Pharmacology and Pharmacokinetics of TB Drugs, Mayo Conference (Webinar) February 11, 2015.
26. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, May 6, 2015.
27. Optimizing the Use of Long Half Life Drugs. NIH workshop: Developing Novel Strategies to Optimize Design of TB Drug Combinations. June 16-17, 2015, Rockville, MD.
28. Advanced Concepts in Pediatric TB - Webinar Series - Pharmacotherapeutics of TB Drugs. Southeastern National TB Center (SNTC), Gainesville, FL, June 18, 2015
29. Maximizing Rifamycins. Southeastern National TB Center (SNTC) Webinar, Gainesville, FL, January 27, 2016
30. Population Pharmacokinetics of AZD-5847 in Patients with TB. Optimization of Oxazolidinones for use in TB Drug Regimens Workshop, NIH, 5601 Fishers Lane, Rockville, Wednesday, December 14th - Thursday, December 15th, 2016.
31. Therapeutic Drug Monitoring (TDM): Practical Questions and Answers. Difficult Dilemmas and Cutting Edge Solutions: Advanced Topics in TB. Workshop, Curry International TB Center, Walnut Creek, CA March 8, 2017
32. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, April 5, 2017.
33. Assessing Pharmacokinetics in Clinical Studies. FDA Meeting on Development of New Tuberculosis Drug Regimens-Scientific and Clinical Design Considerations. Silver Spring, MD, July 19, 2017
34. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, September 19, 2017.
35. Pharmacology and Pharmacokinetics of TB Drugs. Southeastern National TB Center (SNTC) Comprehensive Clinical TB Course, Gainesville, FL, November 14, 2017.
36. Therapeutic Drug Monitoring (TDM): Practical Questions and Answers. Difficult Dilemmas and Cutting Edge Solutions: Advanced Topics in TB. Workshop, Heartland National TB Center, San Antonio, TX, November 3, 2017

F. 3. Other Lectures (from 2009)

Pharmacokinetics and Pharmacodynamics in the treatment of TB.

ID Conference, UF, Gainesville, FL, January 8, 2010

ID Conference, Florida Department of Health, Jacksonville, FL, March 10, 2010

TB and Respiratory Disease Institute, American Lung Association of North Carolina, July 12, 2010

Research Conference, UF Center for AIDS/HIV Research, Jacksonville, FL, July 19, 2010

Orlando Regional Medical Center, Orlando, FL, July 23, 2010

Tuberculosis. Pediatric Pulmonary Conference. June 11, 2010, Gainesville, FL

Pharmacokinetics 101. Grand Rounds, UF Center for AIDS/HIV Research, Jacksonville, FL, July 19, 2010

Emerging Pathogens. FSHP 44th Annual Meeting. Orlando, FL. July 30-August 1, 2010.

Drug-Drug Interactions and Issues Related to TB Drugs in HIV Patients, Area Health Education Centers (AHEC) Sumposium: An HIV/AIDS Update. September 1, 2010, Gainesville, FL

Pharmacokinetics of Anti-tuberculosis Agents and Therapeutic Drug Monitoring. At the Tuberculosis Clinical Update, November 16, 2011, Richmond, VA

Drug-Drug Interactions and Issues Related to TB Drugs in HIV Patients, Area Health Education Centers (AHEC) Sumposium: An HIV/AIDS Update. August 7, 2013, Gainesville, FL

Therapeutic Drug Monitoring and Tuberculosis, Practical Considerations. University of Houston, July 3, 2014.

Pharmacokinetic Variability and Tuberculosis Treatment Outcomes. University of Florida Pediatric Noon Conference. January 27, 2015.

Pharmacokinetics of TB drugs in HIV Co-infected Patients. St Jude Children's Research Hospital and University of South Florida. April 7, 2015.

Pole Vaulting with Rifamycins. PTR Seminar December 10, 2015.

IDPL research 2018. UF IDGM Research Conference, January 31, 2018.

E. Books and Guides

1. Contributor to: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis [online]. 2007. Available from URL: http://www.cdc.gov/tb/TB_HIV_Drugs/default.htm
2. Contributor to: Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2008: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 2nd edition. Braun JT, Daley CL, Desmond EP, Flood JM, Kawamura LM, Loeffler AM, Mase SR, Pai M, **Peloquin C**, Raftery A, Salfinger M, Schechter G, Seaworth BJ, Smith KL, Wallis K. Editors: Loeffler AL, Daley CL, Flood JM, Schechter G.
3. Contributor to: Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2009: Tuberculosis Drug Information Guide. Loeffler AL, **Peloquin CA**, Schechter G. Editors: Loeffler AL, Schechter G, Daley CL, Flood JM.
4. Contributor to: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Vol. 58 / RR-4, April 10, 2009.
5. Contributor to: Loeffler AL, **Peloquin CA**, Schechter G. Editors: Loeffler AL, Schechter G, Daley CL, Flood JM. Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2012: Tuberculosis Drug Information Guide, 2nd edition.
6. Contributor to: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Downloaded from <http://aidsinfo.nih.gov/guidelines> on 5/14/2013
7. Contributor to: CDC. Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis. 2013. Available at [URL:http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/pdf/tbhiv.pdf](http://www.cdc.gov/tb/publications/guidelines/TB_HIV_Drugs/pdf/tbhiv.pdf)
8. Contributor to: Francis J. Curry National Tuberculosis Center and State of California Department of Public Health, 2016: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, 3rd edition. Barry PM, Cattamanchi A, Chen L, Daley CL, Flood JM, Griffith DE, Lin SYG, Loeffler AM, Pascopella L, **Peloquin CA**, Raftery A, Schechter GF, Seaworth BJ, True L. Editors: Chen L, Schechter GF, Daley CL, Flood JM, Loeffler AM, Wallis K.
9. Contributor to: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid, Susan E. Dorman, Narges Alipanah, Pennan M. Barry, Jan L. Brozek, Adithya Cattamanchi, Lelia H. Chaisson, Richard E. Chaisson, Charles L. Daley, Malgosia Grzemska, Julie M. Higashi, Christine S. Ho, Philip C. Hopewell, Salmaan A. Keshavjee, Christian Lienhardt, Richard Menzies, Cynthia Merrifield, Masahiro Narita, Rick O'Brien, **Charles A. Peloquin**, Ann Raftery, Jussi Saukkonen, H. Simon Schaaf, Giovanni Sotgiu, Jeffrey R. Starke, Giovanni Battista Migliori, and Andrew Vernon.
Clin Infect Dis. 2016 Oct 1;63(7):e147-e195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10.
PMID: 27516382

E. Books and Guides (continued)

10. Contributor to: Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Downloaded from <http://aidsinfo.nih.gov/guidelines> on 3/13/2017

F. Manuscripts *Accepted* for Publication

Shemi L. Benge, M. Tobias Heinrichs, Sarah E. Crevasse, Behrang Mahjoub, **Charles A. Peloquin**, and James F.X. Wellehan Jr. A preliminary analysis of pharmacokinetics of ponazuril in Red footed tortoises, *Chelonoidis carbonaria*". Journal of Zoo and Wildlife Medicine

G. Chapters *Accepted* for Publication

Egelund EF, **Peloquin CA**. Antimycobacterial Drugs. In Lippincott's Illustrated Reviews: Pharmacology, 7th Edition.

Rocsanna Namdar and Charles Peloquin. Tuberculosis. Pharmacotherapy: principles and practice, 5th Edition

H. Manuscripts *Submitted* for Publication

Veena Venugopalan, Kayihura Manigaba, Samuel Borgert, Jessica Cope, Charles Peloquin, Kenneth Klinker. Training a Drug to Do New Tricks: Insights on stability of meropenem administered as a continuous infusion.

I. Chapters *Submitted* for Publication

Revised 6-18